A Phase 2 interventional study of Pertuzumab in Prostate Cancer, sponsored by Hoffmann-La Roche. Terminated at 11 sites in 6 countries. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-09-18.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche — 3 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Hoffmann-La Roche.
Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 3 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Australia, United Kingdom
Ages 18+ · Men only
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 9 more countries
Ages 18+ · Men only
Genentech, Inc. · Sites in United States, Australia, Canada and 4 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 19 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 1
First in 2003; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 84 across the 11 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
2 of the studies in Prostatic Neoplasms by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05800665Genentech, Inc.A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | 2027-06-30 |
| NCT07567846Genentech, Inc.A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy. Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50 participants may enter either cohort, for a total enrollment between 46 and 73 participants across 9 study centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
Drug: Pertuzumab
Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
Drug: Pertuzumab
Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
Also known as: Perjeta
Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab
Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.
Time frame: Screening, Every 3 weeks up to Week 24
Time to Disease Progression
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.
Time frame: Screening, Every 3 weeks up to a maximum of 18 months
Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.
Time frame: Screening, Weeks 6, 12, 24, 36 and 48
Time to Response
Time to response was the date of the first documentation of PSA response.
Time frame: Screening, Every 3 weeks for a maximum of 18 months
Duration of Response According to PSA Levels
Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.
Time frame: Baseline, Every 3 weeks for a maximum of 18 months
Duration of Response According to RECIST Criteria
For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.
Time frame: Baseline, Weeks 6, 12, 24, 36 and 48
Percentage of Participants Without Progression
Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.
Time frame: Screening, Weeks 3, 6, 9 and 12
Time to Prostate Cancer Pain Progression
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.
Time frame: Every 3 weeks up to a maximum of 18 weeks
Overall Survival
Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.
Time frame: Screening, Every 3 weeks up to a maximum of 18 months
Time to Treatment Failure
Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.
Time frame: Every 3 weeks up to a maximum of 18 weeks
Change From Baseline in Bone Alkaline Phosphatase
Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).
Time frame: Screening, Weeks 6, 12, 24, 36 and 48
Change From Baseline in N-Telopeptide
In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).
Time frame: Screening, Weeks 6, 12, 24, 36 and 48
Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg\*day/mL)
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab
The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Maximum Plasma Concentration of Pertuzumab
Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Terminal Elimination Half-Life (t1/2) of Pertuzumab
t1/2 is the time in days required for the concentration of the drug to reach half of its original value
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Serum Clearance of Pertuzumab
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Volume of Distribution at Steady State of Pertuzumab
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Mean Residence Time (MRT) of Pertuzumab
MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.
Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
| Milestone | Pertuzumab 420 Milligrams (mg) - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Started | 35 | 33 |
| Completed | 0 | 0 |
| Not completed | 35 | 33 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Insufficient therapeutic response | 31 | 29 |
| Withdrew: Refused treatment | 0 | 3 |
Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.
| percentage of participants | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Objective response | 0.0 | 0.0 |
| Non-response | 34.3 | 30.3 |
| PD | 65.7 | 66.7 |
| Missing | 0.0 | 3.0 |
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.
| weeks | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Time to Disease Progression | 5.6 (2.8 to 20.9) | 6.1 (2.7 to 17.9) |
Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.
No measurements were reported for this outcome.
Time to response was the date of the first documentation of PSA response.
No measurements were reported for this outcome.
Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.
No measurements were reported for this outcome.
For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.
No measurements were reported for this outcome.
Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.
| percentage of participants | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Percentage of Participants Without Progression | 20.0 | 18.2 |
Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.
No measurements were reported for this outcome.
Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.
No measurements were reported for this outcome.
Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.
| days | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Time to Treatment Failure | 6.1 (2.8 to 20.9) | 6.1 (2.7 to 17.9) |
Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).
No measurements were reported for this outcome.
In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).
No measurements were reported for this outcome.
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg\*day/mL)
| µg*day/mL | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab | 3488 ± 44 | 5097 ± 71 |
The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
| µg*day/mL | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab | 2305 ± 22 | 2626 ± 28 |
Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).
| μg/mL | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Maximum Plasma Concentration of Pertuzumab | 255 ± 23 | 294 ± 24 |
Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.
| days | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Pertuzumab | 0.073 ± 11 | 0.074 ± 6 |
t1/2 is the time in days required for the concentration of the drug to reach half of its original value
| days | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Terminal Elimination Half-Life (t1/2) of Pertuzumab | 13.7 ± 39 | 19.3 ± 69 |
Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).
| mL/day | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Serum Clearance of Pertuzumab | 270 ± 29 | 253 ± 35 |
The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.
| mL | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Volume of Distribution at Steady State of Pertuzumab | 4452 ± 26 | 5227 ± 24 |
MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.
| days | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Mean Residence Time (MRT) of Pertuzumab | 18.1 ± 42 | 25.7 ± 77 |
Collected over Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pertuzumab 420 mg - Cohort A | — | 9/35 (25.7%) | 28/35 (80%) |
| Pertuzumab 1050 mg - Cohort B | — | 6/33 (18.2%) | 24/33 (72.7%) |
| Event | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| Urinary retentionRenal and urinary disorders | 3/35 | 0/33 |
| Abdominal PainGastrointestinal disorders | 0/35 | 1/33 |
| HemastemisisGastrointestinal disorders | 0/35 | 1/33 |
| Ileus ParalyticGastrointestinal disorders | 0/35 | 1/33 |
| NauseaGastrointestinal disorders | 0/35 | 1/33 |
| Central Line InfectionInfections and infestations | 0/35 | 1/33 |
| SepsisInfections and infestations | 0/35 | 1/33 |
| Metastatic PainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 1/33 |
| Deep Vein ThrombosisVascular disorders | 0/35 | 1/33 |
| Renal FailureRenal and urinary disorders | 1/35 | 0/33 |
| Event | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/35 | 17/33 |
| FatigueGeneral disorders | 15/35 | 4/33 |
| NauseaGastrointestinal disorders | 11/35 | 2/33 |
| AnorexiaMetabolism and nutrition disorders | 8/35 | 2/33 |
| BackpainMusculoskeletal and connective tissue disorders | 5/35 | 2/33 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 3/35 | 4/33 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 3/35 | 4/33 |
| RashSkin and subcutaneous tissue disorders | 3/35 | 4/33 |
| VomitingGastrointestinal disorders | 4/35 | 0/33 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/35 | 0/33 |
Intent-to-Treat (ITT) population consisted of all participants enrolled and who received at least one dose of study medication.
| Age, Continuous(years) | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B | Total |
|---|---|---|---|
| Mean | 70.8 ± 7.45 | 71.2 ± 6.01 | 71.0 ± 6.74 |
| Sex: Female, Male(Participants) | Pertuzumab 420 mg - Cohort A | Pertuzumab 1050 mg - Cohort B | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 35 | 33 | 68 |
The record gives a start of Sep 2003, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 10 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pertuzumab